Neurological Instability in Ischemic Stroke: Relation with Outcome, Latency Time, and Molecular Markers.
Glutamate
Interleukin
Latency time
Neurological instability
Stroke
Journal
Translational stroke research
ISSN: 1868-601X
Titre abrégé: Transl Stroke Res
Pays: United States
ID NLM: 101517297
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
26
03
2020
accepted:
01
06
2021
revised:
27
05
2021
pubmed:
25
6
2021
medline:
30
4
2022
entrez:
24
6
2021
Statut:
ppublish
Résumé
The National Institutes of Health Stroke Scale (NIHSS) is commonly used to evaluate stroke neurological deficits and to predict the patient's outcome. Neurological instability (NI), defined as the variation of the NIHSS in the first 48 h, is a simple clinical metric that reflects dynamic changes in the area of the brain affected by the ischemia. We hypothesize that NI may represent areas of cerebral instability known as penumbra, which could expand or reduce brain injury and its associated neurological sequels. In this work, our aim was to analyze the association of NI with the functional outcome at 3 months and to study clinical biomarkers associated to NI as surrogate biomarkers of ischemic and inflammatory penumbrae in ischemic stroke (IS) patients. We included 663 IS patients in a retrospective observational study. Neutral NI was defined as a variation in the NI scale between - 5 and 5% (37.1%). Positive NI is attributed to patients with an improvement of > 5% NI after 48 h (48.9%), while negative NI is assigned to patients values lower than - 5% (14.0%). Poor outcome was assigned to patients with mRS ≥ 3 at 3 months. We observed an inverse association of poor outcome with positive NI (OR, 0.35; 95%CI, 0.18-0.67; p = 0.002) and a direct association with negative NI (OR, 6.30; 95%CI, 2.12-18.65; p = 0.001). Negative NI showed a higher association with poor outcome than most clinical markers. Regarding good functional outcome, positive NI was the marker with the higher association (19.31; CI 95%, 9.03-41.28; p < 0.0001) and with the highest percentage of identified patients with good functional outcome (17.6%). Patients with negative NI have higher glutamate levels compared with patients with neutral and positive NI (p < 0.0001). IL6 levels are significantly lower in patients with positive NI compared with neutral NI (p < 0.0001), while patients with negative NI showed the highest IL6 values (p < 0.0001). High glutamate levels were associated with negative NI at short latency times, decreasing at higher latency times. An opposite trend was observed for inflammation, and IL6 levels were similar in patients with positive and negative NI in the first 6 h and then higher in patients with negative NI. These results support NI as a prognosis factor in IS and the hypothesis of the existence of a delayed inflammatory penumbra, opening up the possibility of extending the therapeutic window for IS.
Identifiants
pubmed: 34165728
doi: 10.1007/s12975-021-00924-2
pii: 10.1007/s12975-021-00924-2
pmc: PMC8918467
doi:
Substances chimiques
Biomarkers
0
Glutamates
0
Interleukin-6
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
228-237Informations de copyright
© 2021. The Author(s).
Références
Stroke. 2011 Jan;42(1 Suppl):S7-11
pubmed: 21164112
Stroke. 1996 Jun;27(6):1060-5
pubmed: 8650715
Ann Neurol. 2018 Aug;84(2):260-273
pubmed: 30014516
Neurochem Int. 2012 Apr;60(5):495-505
pubmed: 22361061
Front Neurol. 2019 Apr 17;10:388
pubmed: 31057479
Stroke. 2013 Jul;44(7):1988-96
pubmed: 23743972
Stroke. 2013 Sep;44(9):2513-8
pubmed: 23881960
QJM. 2006 Sep;99(9):625-33
pubmed: 16905751
Stroke. 2016 Sep;47(9):2386-96
pubmed: 27491739
J Automat Chem. 1986;8(4):170-7
pubmed: 18925132
Transl Stroke Res. 2018 Aug;9(4):347-355
pubmed: 29116527
Lancet Neurol. 2015 Jul;14(7):758-67
pubmed: 26067128
Stroke. 1997 Apr;28(4):708-10
pubmed: 9099183
Stroke. 2017 Oct;48(10):2739-2745
pubmed: 28887396
J Cereb Blood Flow Metab. 2011 Jun;31(6):1387-93
pubmed: 21266984
EBioMedicine. 2019 Jan;39:118-131
pubmed: 30555045
BMC Neurol. 2018 Oct 3;18(1):164
pubmed: 30285659
Lancet. 1997 Jan 11;349(9045):79-83
pubmed: 8996418
Cerebrovasc Dis. 1999 Jan-Feb;9(1):22-7
pubmed: 9873159
Sci Rep. 2020 Feb 26;10(1):3513
pubmed: 32103074
Eur Stroke J. 2016 Mar;1(1):20-27
pubmed: 31008264
Ther Adv Neurol Disord. 2018 Jul 30;11:1756286418789854
pubmed: 30083232
Chin Med J (Engl). 2018 Jan 20;131(2):137-143
pubmed: 29336360
Stroke. 2002 May;33(5):1301-7
pubmed: 11988607
Stroke. 2019 Jun;50(6):1339-1345
pubmed: 31084338
Stroke. 2002 Sep;33(9):2197-203
pubmed: 12215587
Neurology. 2004 Jun 22;62(12):2187-92
pubmed: 15210880
J Neuroimmunol. 2003 Jun;139(1-2):93-101
pubmed: 12799026
J Intern Med. 2006 Oct;260(4):343-9
pubmed: 16961671
Crit Care. 2013 Mar 16;17(2):R45
pubmed: 23497639
J Cereb Blood Flow Metab. 2016 Feb;36(2):292-301
pubmed: 26661174
Neurology. 2005 Jun 28;64(12):2115-20
pubmed: 15985583
Circ Res. 2017 Feb 3;120(3):541-558
pubmed: 28154103